Khaled Musallam/LinkedIn
Nov 20, 2025, 16:47
Khaled Musallam Takes on The Role as Chief of Cell/Gene Therapies and Hematology at Burjeel Cancer Institute
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”Priviliged to be working with my friend Prof.Humaid Al-Shamsi to build on the strong foundations of BCI and lead the expansion of hematology services across the network, including dedicated programs in both classical (benign) and malignant hematology, and advanced cell and gene therapies through innovative clinical trials and strategic international partnerships with industry innovators.”
Stay updated with Hemostasis Today.
-
Nov 20, 2025, 18:20Joseph Italiano: Join Us to Pursue Cutting-Edge Research at the Interface of Megakaryocyte Biology
-
Nov 20, 2025, 18:06Akshat Jain Explores a New Blood Journals Study on the Bleeding Burden in Type 1 VWD
-
Nov 20, 2025, 17:40Marilena Vrana Announces the IPPC 2026 – Save the Date!
-
Nov 20, 2025, 17:29Thomas Pincez and Colleagues on Alterations in ITP
-
Nov 20, 2025, 17:11Nita Radhakrishnan Elected as a Fellow of the National Academy of Medical Sciences, Ministry of Health and Family Welfare
-
Nov 20, 2025, 16:26Sarah Matuja Presents Lessons from Tanzania’s Journey at UK Stroke Forum 2025
-
Nov 20, 2025, 15:12Joelle Hochman Wants To Hear Your Blood Clot Story!
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025